Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With…
BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the…